ArticleNature reviews. Immunology2020
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?
Article in Nature reviews. Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Trial
- Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Cancer cell · 2024Trial
- Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.Science (New York, N.Y.) · 2021Trial
- Enterotype-specific microbial biomarkers of immune checkpoint inhibitor response revealed by large-scale integrated metagenomic analysis.Cancer immunology, immunotherapy : CII · 2026Article
- Superparamagnetic iron oxide nanoparticle restores gut microbiota homeostasis to enhance lung cancer immunotherapy.National science review · 2026Article
- Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.Oncoimmunology · 2025Article
- Pharmacomicrobiomics.Clinical pharmacology and therapeutics · 2025Review
- Mathematical Modeling and Association Analysis Decipher the Impact of the Gut Microbiome on Cancer Immunotherapy.Cancer research · 2025Article
- Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.Journal of hematology & oncology · 2025Review
- Global research trends on the interaction between gut microbiome and bile acids: a bibliometric and visualized analysis.Frontiers in cellular and infection microbiology · 2025Article
- Targeting cGAS-STING: modulating the immune landscape of hepatic diseases.Frontiers in immunology · 2025Review
- Autoprobiotics in the Treatment of Patients with Colorectal Cancer in the Early Postoperative Period.Microorganisms · 2024Article
- Getting off tract: contributions of intraorgan microbiota to cancer in extraintestinal organs.Gut · 2023Review
- Influence of tumor mycobiome on cancer pathogenesis (Review).Oncology letters · 2023Review
- Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors.Nature reviews. Clinical oncology · 2023Review
- The Microbiome in Advanced Melanoma: Where Are We Now?Current oncology reports · 2023Review
- The Value of Microbes in Cancer Neoantigen Immunotherapy.Pharmaceutics · 2023Review
- Immune checkpoint blockade breaches the mucosal firewall to induce gut microbiota translocation.Nature reviews. Immunology · 2023Article
- Article
- The Impact of Gut Microbiota-Derived Metabolites on the Tumor Immune Microenvironment.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
There is currently much interest in defining how the microbiota shapes immune responses in the context of cancer. Various studies in both mice and humans have associated particular commensal species with better (or worse) outcomes in different cancer types and following treatment with cancer immunotherapies. However, the mechanisms involved remain ill-defined and even controversial. In this Viewpoint, Nature Reviews Immunology has invited six eminent scientists in the field to share their thoughts on the key questions and challenges for the field.
Indexed as
Identifiers
32661409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.